Key Takeaways
- • ValueAct Capital founder Jeffrey W. Ubben is transitioning control of the firm's $16 billion portfolio to Mason Morfit, promoting rare succession continuity in the hedge fund industry while Ubben remains as chief executive.
- • Morfit, hired as one of ValueAct's first employees in 2000, has nearly two decades of experience and holds board seats at major holdings including Microsoft and Valeant Pharmaceuticals, positioning him to maintain the firm's investment philosophy.
- • ValueAct's activist investment approach has delivered annualized returns of 15 percent annually, significantly outperforming the broader hedge fund industry, which has struggled with the HFR Global Hedge Fund index up only 2 percent year-to-date versus the S&P 500's 7 percent gain.
- • The succession addresses a critical challenge in hedge fund management: maintaining founder-led performance and philosophy after leadership transitions, with Ubben's continued role as CEO designed to provide continuity without micromanagement.
- • ValueAct's constructive activism model—focusing on behind-the-scenes corporate governance improvements rather than public campaigns—differentiates the firm in a competitive landscape where most hedge funds have failed to justify their fee structures.
Summary
ValueAct Capital is executing a deliberate succession plan that underscores the firm's commitment to the governance principles it advocates to its portfolio companies. Founder Jeffrey W. Ubben, known for his low-profile approach to activist investing, is promoting Mason Morfit to chief investment officer, effectively transferring day-to-day control of the hedge fund's $16 billion portfolio while retaining his own position as chief executive. This arrangement signals a departure from the typical hedge fund succession model, where founder departures often trigger capital flight or strategic shifts.
Morfit's elevation represents institutional depth rare in the alternative asset management industry. As one of ValueAct's first hires following the firm's 2000 founding, Morfit has spent nearly two decades embedded in ValueAct's investment process and culture. His responsibilities have extended to board-level engagement with major holdings, including positions at Microsoft and Valeant Pharmaceuticals, giving him direct exposure to ValueAct's core investment thesis and stakeholder management strategy. This lengthy apprenticeship distinguishes Morfit from typical hedge fund successors and positions him to maintain continuity in the firm's contrarian, long-term engagement approach.
ValueAct's track record provides material context for the succession's significance. The firm has achieved annualized returns of 15 percent annually—a substantial outperformance margin at a time when hedge funds broadly are struggling to justify their cost structures. Year-to-date performance in 2017 illustrates the challenge facing the broader industry: the HFR Global Hedge Fund index has returned only 2.1 percent, trailing the S&P 500's 7 percent gain. ValueAct's success derives partly from its distinctive philosophy, which emphasizes constructive activism and behind-the-scenes corporate governance work rather than public campaigns or hostile confrontation. This approach requires deep relationship management and long-term conviction—qualities that Morfit has demonstrated over his tenure.
The succession plan also addresses a governance contradiction inherent to activist hedge funds. ValueAct's founder has built a reputation for pressuring portfolio companies to implement orderly leadership transitions and robust succession planning—best practices he is now applying to his own firm. Ubben's decision to remain as chief executive while delegating investment authority to Morfit creates potential friction points common to founder-era transitions, but the structure appears designed to provide strategic oversight without operational micromanagement. Success will depend on both parties' ability to navigate this bifurcated authority.
Morfit's elevation represents institutional depth rare in the alternative asset management industry. As one of ValueAct's first hires following the firm's 2000 founding, Morfit has spent nearly two decades embedded in ValueAct's investment process and culture. His responsibilities have extended to board-level engagement with major holdings, including positions at Microsoft and Valeant Pharmaceuticals, giving him direct exposure to ValueAct's core investment thesis and stakeholder management strategy. This lengthy apprenticeship distinguishes Morfit from typical hedge fund successors and positions him to maintain continuity in the firm's contrarian, long-term engagement approach.
ValueAct's track record provides material context for the succession's significance. The firm has achieved annualized returns of 15 percent annually—a substantial outperformance margin at a time when hedge funds broadly are struggling to justify their cost structures. Year-to-date performance in 2017 illustrates the challenge facing the broader industry: the HFR Global Hedge Fund index has returned only 2.1 percent, trailing the S&P 500's 7 percent gain. ValueAct's success derives partly from its distinctive philosophy, which emphasizes constructive activism and behind-the-scenes corporate governance work rather than public campaigns or hostile confrontation. This approach requires deep relationship management and long-term conviction—qualities that Morfit has demonstrated over his tenure.
The succession plan also addresses a governance contradiction inherent to activist hedge funds. ValueAct's founder has built a reputation for pressuring portfolio companies to implement orderly leadership transitions and robust succession planning—best practices he is now applying to his own firm. Ubben's decision to remain as chief executive while delegating investment authority to Morfit creates potential friction points common to founder-era transitions, but the structure appears designed to provide strategic oversight without operational micromanagement. Success will depend on both parties' ability to navigate this bifurcated authority.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.